Journal
RESVERATROL AND HEALTH
Volume 1290, Issue -, Pages 59-66Publisher
BLACKWELL SCIENCE PUBL
DOI: 10.1111/nyas.12145
Keywords
resveratrol; phytoestrogen; osteogenesis; osteoporosis; menopause
Funding
- European Commission Framework 7 program (EUFP7) [HEALTH.2012.2.4.5-2, 305815]
- Arthritis Research U.K.
- Medical Research Council
Ask authors/readers for more resources
There are a number of pharmacological agents for the treatment of bone mineral loss and osteoporosis. Hormone replacement therapy (HRT) with estrogen is an established treatment, but it has several adverse side effects and can increase the risk of cancer, heart disease, and stroke. There is increasing interest in nutritional factors and naturally occurring phytochemical compounds with the potential for preventing age-related and postmenopausal bone loss. Resveratrol (3,5,4'-trihydroxy-trans-stilbene) is a polyphenolic phytoestrogen with osteogenic and osteoinductive properties. It can modify the metabolism of bone cells and has the capacity to modulate bone turnover. This paper provides an overview of current research on resveratrol and its effects on bone cells in vitro, highlighting the challenges and opportunities facing this area of research, especially in the context of providing nutritional support for postmenopausal women who may not benefit from HRT and older patients with various forms of arthritis, metabolic bone disease, and osteoporosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available